Clot-Dissolving Treatment Through a Catheter for Stroke From a Blocked Medium-Sized Brain Artery
Tests catheter-delivered clot-dissolving treatment in adults with stroke from a blocked medium-sized artery.
Plain-language title generated from the registry record
Registry title: IAT-MeVO Trial Domain Within the ACT-GLOBAL Adaptive Platform Trial
Key facts
- Where
- Chengdu, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a stroke caused by a blocked medium-sized brain artery who cannot have the clot-dissolving drug through a vein and can start within 24 hours. It compares a procedure with clot-dissolving drug given inside the artery against standard medical care.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Stroke from a blockage in a single medium-sized brain artery (parts of the MCA, ACA or PCA), confirmed by CT or MR angiography. Less than 24 hours from onset or last seen well. NIHSS 5 or higher, or NIHSS 4 or lower with a disabling deficit or fluctuating symptoms. Brain scan criteria depend on time since onset.
- Earlier treatment
- Must not have had intravenous thrombolysis and be considered unable to have it by the treating clinician.
Main reasons for not taking part
- Bleeding in the brain on the scan
- Two or more blocked brain arteries at the same time
- Severe kidney problems or severe contrast dye allergy
- Bleeding disorder, low platelets or abnormal blood clotting
- Pregnancy or breastfeeding
Read by machine on 9 November 2026.
Where in China
- West China Hospital of Sichuan UniversityChengdu, ChinaContact: Bo WuNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Bo Wu
- Trial code
- NCT07336927
- Record updated
- 15 January 2026
- Original description
IAT-MeVO is an international, multicenter, prospective, randomised, open-label, blinded end-point assessed (PROBE) trial, to evaluate the efficacy and safety of endovascular therapy (EVT) [intra-arterial thrombolysis (IAT)-based] versus best medical management (BMT) in patients with acute ischemic stroke (AIS) due to medium vessel occlusion (MeVO) who are ineligible for intravenous thrombolysis (IV) within 24 h of onset.Read full original descriptionShow less
Efficacy and Safety of Endovascular Therapy With Intra-Arterial Thrombolysis for Medium Vessel Occlusion Stroke--the IAT-MeVO Trial
IAT-MeVO is an international, multicenter, prospective, randomised, open-label, blinded end-point assessed (PROBE) trial, to evaluate the efficacy and safety of endovascular therapy (EVT) [intra-arterial thrombolysis (IAT)-based] versus best medical management (BMT) in patients with acute ischemic stroke (AIS) due to medium vessel occlusion (MeVO) who are ineligible for intravenous thrombolysis (IV) within 24 h of onset.
Inclusion: Age ≥ 18 y; Diagnosed as acute ischemic stroke; Isolated medium distal vessel occlusion (i.e. an occlusion of the M2, the M3/M4 segment of the MCA, the A1/ A2/A3 segment of the ACA or the P1/P2/P3 segment of the PCA) confirmed by CT or MR Angiography; Time from onset (or last-seen-well) to randomization < 24h; Has not received intravenous thrombolysis and is considered unsuitable for it based on the treating clinician's assessment; NIHSS ≥ 5, or NIHSS ≤ 4 with disabling deficit (e.g. severe aphasia, hemianopia, hemiplegia/loss of function in one side) or fluctuating symptoms at the time of randomization; For patients within 6 h of onset: No visually apparent hypodensity is observed on non-contrast CT compared with the contralateral white matter, or no hyperintensity is seen on fluid-attenuated inversion recovery (FLAIR) imaging; For patients presenting 6-24 h after onset: A perfusion imaging-based ischemic core mismatch ratio >1.2 and an infarct core volume <50 mL are required; Pre-stroke mRS ≤ 1；; Patient/Legally Authorized Representative has signed the Informed Consent form.
Exclusion: Concurrent multiple (≥2) intracranial arterial occlusions; Concurrent participation in another investigational drug or device study that could interfere with the present trial; Any evidence of intracranial hemorrhage on qualifying imaging; Any terminal disease with life expectancy <1 year; Clinical assessment of conditions unsuitable for interventional therapy (e.g., severe contrast agent allergy or absolute contraindications to iodine contrast agent; severe renal insufficiency, glomerular filtration rate < 30ml/min or serum creatinine > 220μmol/L (2.5 mg/dl)); Unsuitable for arterial thrombolytic therapy (e.g., known history of hereditary or acquired hemorrhagic disease and/or platelet count <50×109/L; abnormal coagulation function (INR>1.7); oral anticoagulants were taken within 24 - 48 hours before onset within APTT > 3 times normal; recent medical history or clinical manifestations of brain tumors other than meningiomas); Suspected cerebral vasculitis, septic embolism, or infective endocarditis as the cause of vessel occlusion; Suspected arterial dissection; Pregnancy or lactation; Other circumstances that participation is not deemed appropriate.